Although it is a standard policy to treat patients with PBC with UDCA, OCA and PPAR agonists which mainly improve cholestasis, PBC is an autoimmune disease, and a novel therapeutic agent that can suppress the origin of inflammation is needed in order to cure PBC itself fundamentally. Here, PPARA is linked to autoimmune disease.